MoonLake Immunotherapeutics (MLTX) Non-Current Deffered Revenue (2020 - 2022)
MoonLake Immunotherapeutics (MLTX) posted quarterly Non-Current Deffered Revenue of $4.0 million for Q1 2022, little changed year-over-year from $4.0 million in Q1 2021, and little changed quarter-over-quarter from $4.0 million in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Non-Current Deffered Revenue (2020 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2022.
- In Q1 2022, Non-Current Deffered Revenue changed 0.0% year-over-year to $4.0 million; the TTM figure through Mar 2022 stood at $4.0 million (changed 0.0% YoY), while the FY2021 annual figure was $4.0 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue for Q1 2022 stood at $4.0 million, roughly flat from $4.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $4.0 million in Q4 2020, with the low at $4.0 million in Q4 2020.
- The 3-year median for Non-Current Deffered Revenue is $4.0 million (2020), against an average of $4.0 million.
- Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
- MoonLake Immunotherapeutics' Non-Current Deffered Revenue stood at $4.0 million in 2020, then changed by 0.0% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022.
- Business Quant data shows MLTX's Non-Current Deffered Revenue at $4.0 million in Q1 2022, $4.0 million in Q4 2021, and $4.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 4.03 Mn |
| Sep 30, 2021 | 4.03 Mn |
| Jun 30, 2021 | 4.03 Mn |
| Mar 31, 2021 | 4.03 Mn |
| Dec 31, 2020 | 4.03 Mn |